Aequus Pharmaceuticals (CVE:AQS) Trading 25% Higher

Aequus Pharmaceuticals Inc. (CVE:AQSGet Free Report)’s share price shot up 25% on Monday . The company traded as high as C$0.03 and last traded at C$0.03. 512,000 shares changed hands during mid-day trading, an increase of 118% from the average session volume of 234,754 shares. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Stock Up 25.0 %

The firm’s 50-day moving average is C$0.02 and its two-hundred day moving average is C$0.02. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.09. The stock has a market cap of C$3.32 million, a P/E ratio of -1.00 and a beta of 0.17.

Aequus Pharmaceuticals Company Profile

(Get Free Report)

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.

Read More

Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.